Clinical Predictive Circulating Peptides in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy
暂无分享,去创建一个
M. Ferrari | A. Giordano | M. Agostini | D. Nitti | E. Tasciotti | P. Traldi | F. Rizzolio | C. Bedin | S. Crotti | S. Pucciarelli | M. Enzo | P. Del Bianco | I. Maretto | G. Toffoli
[1] M. Ferrari,et al. Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer. , 2014, Clinical chemistry.
[2] Gui-yuan Li,et al. Analysis of the raw serum peptidomic pattern in glioma patients. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[3] Ji-fan Hu,et al. Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia , 2013, Oncology letters.
[4] S. Nicolardi,et al. Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors. , 2012, Journal of proteomics.
[5] Paul Dowling,et al. Analysis of acute‐phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer , 2012, International journal of cancer.
[6] Ben C. Collins,et al. Serum Proteomic Profiling Reveals That Pretreatment Complement Protein Levels are Predictive of Esophageal Cancer Patient Response to Neoadjuvant Chemoradiation , 2011, Annals of surgery.
[7] M. Ferrari,et al. Microfluidic enrichment of small proteins from complex biological mixture on nanoporous silica chip. , 2011, Biomicrofluidics.
[8] Ronald J. Moore,et al. Blood Peptidome-Degradome Profile of Breast Cancer , 2010, PloS one.
[9] M. Sughrue,et al. Cancer and the Complement Cascade , 2010, Molecular Cancer Research.
[10] Marie-Christine W. Gast,et al. Serum degradome markers for the detection of breast cancer. , 2010, Journal of proteome research.
[11] J. Schellens,et al. Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. , 2010, Oncology reports.
[12] M. Ferrari,et al. Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome , 2010, Proteomics.
[13] M. Ferrari,et al. Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. , 2010, ACS nano.
[14] A. Archakov,et al. Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives. , 2010, Journal of proteomics.
[15] Kun He,et al. Identification of complement C3f‐desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment , 2010, Proteomics.
[16] N. Petrelli,et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Francesco Rulli,et al. Clusterin in Stool: A New Biomarker for Colon Cancer Screening? , 2009, The American Journal of Gastroenterology.
[18] G. Giaccone,et al. Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling , 2009, Proteome Science.
[19] H. McLeod,et al. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. , 2009, International journal of radiation oncology, biology, physics.
[20] John D Lambris,et al. Is complement good or bad for cancer patients? A new perspective on an old dilemma. , 2009, Trends in immunology.
[21] S. Pucci,et al. CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype. , 2009, Advances in cancer research.
[22] Martin Strohalm,et al. mMass data miner: an open source alternative for mass spectrometric data analysis. , 2008, Rapid communications in mass spectrometry : RCM.
[23] Ramón Díaz-Uriarte,et al. GeneSrF and varSelRF: a web-based tool and R package for gene selection and classification using random forest , 2007, BMC Bioinformatics.
[24] Wayne F. Patton,et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. , 2007, Clinical chemistry.
[25] J. Skibber,et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer , 2007, Cancer.
[26] E. Petricoin,et al. Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy , 2007, Annals of surgery.
[27] Andy Liaw,et al. Classification and Regression by randomForest , 2007 .
[28] E. Petricoin,et al. The blood peptidome: a higher dimension of information content for cancer biomarker discovery , 2006, Nature Reviews Cancer.
[29] Laurence Collette,et al. Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.
[30] J. A. Falkner,et al. ProteomeCommons.org JAF: reference information and tools for proteomics , 2006, Bioinform..
[31] K. Novak. Biomarkers: Taking out the trash , 2006, Nature Reviews Drug Discovery.
[32] A. Olshen,et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.
[33] J. Willis,et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer , 2006, Cell Death and Differentiation.
[34] D. Treanor,et al. Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancer , 2005, Histopathology.
[35] L. Mayo,et al. IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. , 2004, Mutation research.
[36] D. Mierke,et al. Mechanisms regulating the expression, self‐maintenance, and signaling‐function of the bradykinin B2 and B1 receptors , 2002, Journal of cellular physiology.
[37] W. Regine,et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. , 2000, International journal of radiation oncology, biology, physics.
[38] J. Petiot,et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.